Cracking the code: How pancreatic cancer rewires its DNA to dodge treatment

Pancreatic cancer's genetic shapeshifting, decoded

Scientists at NYU Langone Health have uncovered how pancreatic ductal adenocarcinoma (PDAC) — one of the deadliest cancers, with an 85% five-year mortality rate — continuously rewrites its own genetic playbook to become more aggressive, spread, and evade treatment. Published in Nature Genetics, the study is the most detailed single-cell analysis of pancreatic cancer to date.

By examining 443,451 individual cancer cells from 62 tumors, researchers found that each tumor contains 2–11 distinct cell "clones," each with unique genetic traits. Some clones develop resistance to chemotherapy; others become better at invading tissues. Critically, cancer cells can shift between less aggressive ("classical") and more aggressive ("basal") states — a flexibility that fuels disease progression.

Key Takeaways:

• Blocking the MYC gene in aggressive cancer cells reversed them toward a less aggressive state and increased their visibility to immune cells
• Elevated TIGIT gene activity — combined with reduced PD1 activity — may explain why immunotherapies have largely failed against PDAC
• Clinical trials targeting MYC and TIGIT inhibitors are already underway

Why it matters: These findings open a new front in the fight against a notoriously treatment-resistant cancer, suggesting that targeting the genetic mechanisms driving tumor evolution — not just the tumor itself — could be the key to better outcomes.